FDA approves pemetrexed plus cisplatin for non-squamous NSCLC

Langer, Corey J.
October 2008
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p1
The article reports that approval has been given by the U.S. Food and Drug Administration for pemetrexed plus cisplatin as first-line therapy for locally advanced metastatic non-small cell lung cancer (NSCLC) in patients with nonsquamous history. The substance has not been approved for patients with squamous cell NSCLC.


Related Articles

  • Pharmacyclics Re-Files Xcytrin NDA With FDA.  // Bioworld Week;4/30/2007, Vol. 15 Issue 18, p3 

    The article reports on the filing of a new drug application for Xcytrin in combination with standard radiation therapy for non-small-cell lung cancer patients with brain metastasis by Pharmacyclics Inc. Despite a prior refusal from U.S. Food and Drug Administration, the company believes that the...

  • Eli Lilly: Alimta receives US green light for lung cancer.  // PharmaWatch: Monthly Review;Nov2008, Vol. 7 Issue 11, p9 

    The authors reflect on the approval of FDA for Eli Lilly & Co.'s Alimta for use as a first line therapy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin. They refer to NSCLC as a group of histologies where tumor types can be differentiated by...

  • Tarceva approved for first-line treatment of NSCLC.  // Hem/Onc Today;6/10/2013, Vol. 14 Issue 11, p47 

    The article reports that erlotinib was approved by the U.S. Food and Drug Administration as a first-line treatment for patients with metastatic non-small cell lung cancer.

  • FDA Delays Promising Prostate Cancer Vaccine. Faloon, William // Life Extension;Jun2005, Vol. 11 Issue 6, p17 

    Reports on the delay in the U.S. Food and Drug Administration approval of the anti-cancer vaccine in the U.S. Response rate of cancer patients to androgen-deprivation therapy; Improvement in the survival rates of cancer patients; Result of the clinical trials of the anti-cancer vaccine.

  • Eli Lilly lung cancer drug gains FDA approval.  // PharmaWatch: Cancer;October 2004, Vol. 3 Issue 10, p10 

    This article reports that Eli Lilly & Co. lung cancer drug gains FDA approval. Indianapolis-based Eli Lilly has revealed the FDA approval of Alimta to treat the most common form of lung cancer. Alimta secured accelerated approval for the treatment of non-small cell lung cancer after data...

  • Ahead of Panel, FDA Questions Tarceva's Maintenance Benefit. Young, Donna // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p3 

    The article reports on the questions raised by the U.S. Food and Drug Administration (FDA) on the benefit of Tarceva (erlotinib) from OSI Pharmaceutical Inc. as a maintenance therapy for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). It relates that Tarceva demonstrated...

  • AstraZeneca Concedes NSCLC Drug Iressa in U.S. Withdrawal. Boggs, Jennifer // BioWorld Insight;5/29/2012, Vol. 20 Issue 22, p3 

    The article reports on the U.S. Food and Drug Administration's decision to withdraw drug Iressa (gefitinib) manufactured by AstraZeneca PLC, used for lung cancer treatment. It mentions that confirmatory trials does not support the drug approved for monotherapy after its failure in giving...

  • Pharmacyclics Files Xcytrin NDA Through FDA's Protest Procedure. Lorenzo, Aaron // BioWorld Today;4/24/2007, Vol. 18 Issue 79, p3 

    The article reports on the decision of Pharmacyclics Inc. to file a new drug application for the use of Xcytrin in combination with radiation therapy for non-small-cell lung cancer patients. Since the first NDA filed in February 2007 was not accepted, Pharmacyclics filed over protest according...

  • Applications Update.  // PharmaWatch: Biotechnology;Oct2005, Vol. 4 Issue 10, p8 

    The article presents information related to the biotechnology industry. Biogen Idec Inc. and Genentech Inc. are to seek the U.S. Food and Drug Administration clearance for a new indication of the companies' cancer drug Rituxan, to treat patients with active rheumatoid arthritis. Cell...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics